A Medical Device Daily Staff Report
Healthcare Management Systems (HMS; Franklin, Tennessee) has formed a strategic partnership with Greenway Medical Technologies (Carrollton, Georgia) to integrate HMS' enterprise inpatient EHR with Greenway's ambulatory solution, PrimeSUITE. The two companies will jointly sell the Greenway solution to HMS customers.
Through the integration of Greenway's ambulatory solutions, HMS customers will realize greater patient retention, improvements in coordination of care and more fluid data exchange of orders and results with their surrounding clinics. "Greenway is a leader in the ambulatory space, and we share their strategy of improving care and the business of healthcare. We have a number of customers exploring options for their ambulatory solutions, and we are pleased to provide them with industry-leading technology through our newest partner in Greenway," said Steve Starkey, president of HMS. "HMS and Greenway will collaborate to help HMS customers navigate the changing landscape of healthcare while giving clinicians powerful solutions that help enhance data exchange, patient care and safety, and operational efficiency."
As part of the alliance, HMS and Greenway will conduct joint sales and marketing activities. Customers who choose to have Greenway's market-leading solutions integrated with HMS' enterprise EHR will be served by a team of implementation experts from both HMS and Greenway. HMS will continue to manage its enterprise inpatient EHR, while Greenway will implement and support its solutions for HMS customers.
Healthcare Management Systems makes clinical and financial software developed exclusively for community and specialty hospitals. Greenway delivers software and business service solutions for healthcare providers through its PrimeSUITE platform.
In other agreements/contracts news:
• SurgiCount Medical (Irvine, California), the operating subsidiary of Patient Safety Technologies, has signed an agreement with GNYHA Services (New York) to provide the SurgiCount Safety-Sponge System to its health system members.
The Safety-Sponge System is the market leading solution to the most commonly reported surgical "Never Event," retained surgical sponges, and has been clinically proven to eliminate this frequent but preventable error. The agreement provides terms under which GNYHA Services members have access to the Safety-Sponge System for those who select to implement the solution for their retained sponge prevention strategy.
GNYHA Services is a full-service healthcare group purchasing and supply chain efficiency organization, and a wholly owned, for-profit subsidiary of the Greater New York Hospital Association.
• Janssen Biotech (Spring House, Pennsylvania) and Johnson & Johnson Innovation (Cambridge, Massachusetts) reported the establishment of a research alliance with The Icahn School of Medicine at Mount Sinai (New York) to advance the scientific understanding of inflammatory bowel disease (IBD) and the discovery of next-generation therapeutic solutions.
Scientists from the Janssen Immunology Therapeutic Area and researchers from Mount Sinai will work in partnership to investigate disease triggers, identify new opportunities for therapeutic interventions and establish diagnostics to facilitate precision medicine and predictive biomarkers. The industry and academic partnership brings together Janssen research and development capabilities with an early-stage life science investment through the Johnson & Johnson Innovation center in Boston and Mount Sinai's expertise in computational biology, and clinical and translational research in IBD.
The collaboration will focus on building a Molecular Interaction Network of Disease (MIND) in IBD with the breadth and depth to yield high confidence therapeutic hypotheses to be tested in vitro and in vivo. Using preclinical models, clinical study data and patient samples, a dedicated group of Janssen and Mount Sinai researchers, computational biologists and translational medicine scientists will develop clinical methodologies to test hypotheses and identify potential therapeutic candidates.